Education
About Us
Working with TipRanks
Follow Us
Novavax (DE:NVV1)
BERLIN:NVV1
NVV1 Stock Chart & Stats
Day’s Range― - ―
52-Week Range€4.82 - €23.93
Previous CloseN/A
Volume7.16K
Average Volume (3M)72.00
Market Cap
$1.03B
Enterprise ValueN/A
Total Cash (Recent Filing)$923.12M
Total Debt (Recent Filing)$230.42M
Price to Earnings (P/E)2.5
Beta2.50
Next Earnings
Aug 06, 2025EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.61
Shares Outstanding161,970,340
10 Day Avg. Volume66
30 Day Avg. Volume72
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)-1.80
Price to Sales (P/S)0.00
P/FCF Ratio-11.19
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$9.87Price Target Upside54.73% Upside
Rating ConsensusHold
Number of Analyst Covering4
Novavax News
Bulls Say, Bears Say
Bulls Say
Partnership MilestoneThis approval does trigger the $175M milestone from Sanofi which was seen as the most significant near-term risk from the delay.
Product AdvantageThe Novavax vaccine resulted in about half as many negative symptoms compared to current mRNA vaccines, which could be advantageous in the Covid vaccination landscape.
Regulatory ApprovalNVAX shares are trading up +11% after the FDA approved the BLA submission for Nuvaxovid in individuals 65 years or older and individuals 12-64 who have at least one underlying condition that puts them at higher risk for severe outcomes.
Bears Say
Market ValuationCurrent share levels are believed to overvalue the discounted forecasts of associated royalty revenue streams, leading to an underweight rating.
Regulatory ChallengesThe request for another randomized clinical trial for Nuvaxovid increases downside risk for potential milestones/royalties.
Regulatory SetbacksThe less favorable regulatory outlook for the COVID/Flu combo regimen is a setback and a likely impediment to meaningful business development.
Options Prices
Currently, No data available
---
Ownership Overview
0.39% Insiders
12.67%
Mutual Funds
21.01% Other Institutional Investors
48.66% Public Companies and Individual Investors
NVV1 FAQ
What was Novavax’s price range in the past 12 months?
Novavax lowest stock price was €4.82 and its highest was €23.93 in the past 12 months.
What is Novavax’s market cap?
Novavax’s market cap is $1.03B.
When is Novavax’s upcoming earnings report date?
Novavax’s upcoming earnings report date is Aug 06, 2025 which is in 70 days.
How were Novavax’s earnings last quarter?
Novavax released its earnings results on May 08, 2025. The company reported €2.607 earnings per share for the quarter, beating the consensus estimate of -€0.376 by €2.984.
Is Novavax overvalued?
According to Wall Street analysts Novavax’s price is currently Undervalued.
Does Novavax pay dividends?
Novavax does not currently pay dividends.
What is Novavax’s EPS estimate?
Novavax’s EPS estimate is -0.04.
How many shares outstanding does Novavax have?
Novavax has 161,970,340 shares outstanding.
What happened to Novavax’s price movement after its last earnings report?
Novavax reported an EPS of €2.607 in its last earnings report, beating expectations of -€0.376. Following the earnings report the stock price went down -2.106%.
Which hedge fund is a major shareholder of Novavax?
Currently, no hedge funds are holding shares in DE:NVV1
Novavax Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$9.87 (54.73% Upside)
$9.87 (54.73% Upside)
Blogger Sentiment
Bullish
DE:NVV1 Sentiment 72%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $119.6K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-52.14%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-4.47%
Trailing 12-Months
Company Description
Novavax
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
NVV1 Company Deck
NVV1 Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call reflects significant revenue growth and successful cost reduction strategies, alongside strategic partnerships and pipeline advancements. However, challenges remain with regulatory commitments and market penetration for existing products.Read More>NVV1 Stock 12 Month Forecast
Average Price Target
€9.87
▲(54.73%Upside)
Technical Analysis
Anavex Life Sciences
―
CureVac
―
AbCellera Biologics
―
Pharvaris
―
Immunocore Holdings
―